Lv2
178 积分 2025-04-17 加入
Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry
15小时前
已完结
A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs
4天前
已完结
Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions
1个月前
已完结
Why next-generation mechanistic models will transform drug discovery: integrating efficacy and safety
1个月前
已完结
Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates
1个月前
已完结
In vitro reversible enzyme inhibition assays to predict drug-drug interactions: Current state and industry perspective from the IQ Consortium Enzyme Inhibition Working Group
1个月前
已完结
A framework for optimized reaction phenotyping of the seven major hepatic P450 isoforms in human liver microsomes using six mechanism-based inactivators and one reversible inhibitor
1个月前
已关闭
An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation
3个月前
已完结
Compatibility of Caco-2 cells with Simulated Intestinal Fluid-Predicting Permeability
3个月前
已关闭
Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants
4个月前
已完结
皖公网安备34019202002308
